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Abstract 
Background: Low attendance and engagement in behavioural weight management trials are common. Mental 
health may play an important role, however previous research exploring this association is limited with inconsistent 
findings. We aimed to investigate whether mental health was associated with attendance and engagement in a trial 
of behavioural weight management programmes.
Methods: This is a secondary data analysis of the Weight loss referrals for adults in primary care (WRAP) trial, 
which randomised 1267 adults with overweight or obesity to brief intervention, WW (formerly Weight Watchers) 
for 12-weeks, or WW for 52-weeks. We used regression analyses to assess the association of baseline mental health 
(depression and anxiety (by Hospital Anxiety and Depression Scale), quality of life (by EQ5D), satisfaction with life (by 
Satisfaction with Life Questionnaire)) with programme attendance and engagement in WW groups, and trial attend-
ance in all randomised groups.
Results: Every one unit of baseline depression score was associated with a 1% relative reduction in rate of WW ses-
sion attendance in the first 12 weeks (Incidence rate ratio [IRR] 0.99; 95% CI 0.98, 0.999). Higher baseline anxiety was 
associated with 4% lower odds to report high engagement with WW digital tools (Odds ratio [OR] 0.96; 95% CI 0.94, 
0.99). Every one unit of global quality of life was associated with 69% lower odds of reporting high engagement with 
the WW mobile app (OR 0.31; 95% CI 0.15, 0.64). Greater symptoms of depression and anxiety and lower satisfac-
tion with life at baseline were consistently associated with lower odds of attending study visits at 3-, 12-, 24-, and 
60-months.
Conclusions: Participants were less likely to attend programme sessions, engage with resources, and attend study 
assessments when reporting poorer baseline mental health. Differences in attendance and engagement were 
small, however changes may still have a meaningful effect on programme effectiveness and trial completion. Future 
research should investigate strategies to maximise attendance and engagement in those reporting poorer mental 
health.
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Background
Behavioural weight management programmes are inter-
nationally recommended practice for the treatment of 
overweight and obesity [1]. Good evidence shows that 
behavioural programmes benefit physical health [2–5], 
and a recent systematic review suggests there may be 
small benefits for some aspects of mental health, with no 
evidence to suggest that programmes negatively impact 
mental health [6]. However, low attendance and engage-
ment with these programmes are common [7, 8], and 
the reasons for this are poorly understood. Low attend-
ance and engagement can decrease the opportunity for 
participants to gain  the skills, strategies, knowledge, 
and social support offered by the weight management 
programmes [8]. Previous research has reported that 
low levels of attendance and engagement in behavioural 
weight management programmes are associated with 
decreased likelihood of achieving clinically significant 
weight loss, consequently reducing the likelihood of gain-
ing the associated health benefits [9–11], highlighting the 
importance of better understanding the reasons for poor 
attendance and engagement.
Previous research has sought to identify factors asso-
ciated with attendance and engagement in behavioural 
weight management trials, however, findings have been 
constrained by the limited diversity of potentially associ-
ated factors assessed. Demographic factors, such as age, 
deprivation, and gender, have been commonly assessed 
for their association, with evidence suggesting better 
attendance and engagement among people who are older 
in age, more educated, and female [12–14]. However, 
previous research lacks sufficient investigation into how 
mental health may be associated with attendance and 
engagement.
Some researchers have suggested that mental health 
may play an important role in attendance and engage-
ment of behavioural weight management programmes 
and in attrition of trials evaluating these programmes. 
There is a well-evidenced bidirectional relationship 
between obesity and mental health, with poor mental 
health being both a cause and consequence of obesity 
[15–20]. Additionally, both obesity and poor mental 
health are associated with experiencing stigma and dis-
crimination, which is in turn associated with the avoid-
ance of health promoting activities (e.g., behavioural 
weight management programmes) [21–23]. Further-
more, poor mental health can exacerbate feelings of 
amotivation [24–26] and can increase the likelihood to 
socially withdraw and isolate [27–29]. Thus, it is plausi-
ble that mental health may be associated with attendance 
and engagement with a behavioural weight management 
programme. Mental health is increasingly being con-
sidered as a symptom continuum which recognises that 
individuals can experience one or more symptoms of 
mental illness without meeting diagnostic criteria [30, 
31]. Embracing the symptom  continuum-based defini-
tion  of mental health is associated with reduced stigma 
and improved attitudes toward mental ill-health [31, 32].
As stated, previous research lacks sufficient investiga-
tion into the role of mental health in attendance at and 
engagement with behavioural weight management pro-
grammes. The findings of the limited existing research 
findings are conflicting with some evidence reporting 
lower attendance and completion rates among weight 
management participants with higher levels of anxiety 
or depression [13, 33, 34], whilst other research reports 
mental health to not be associated with attendance and 
engagement [35]. A systematic review reported not find-
ing any consistently associated psychological factors, 
though these findings were limited by the small number 
of studies assessing each factor [7]. The limited previous 
research and conflicting evidence highlights a need for 
further research investigating the relationship between 
mental health and attendance at and engagement with 
behavioural weight management programmes.
It is also plausible that mental health may influence 
whether a participant attends study follow-up visits. 
This is important as, although on average mental health 
appears to improve following a behavioural weight 
management programme [6], if baseline mental health 
is associated with attrition then  it is possible that this 
finding may be biased by unrepresentative participant 
samples. Participant samples may be biased to include 
the most mentally healthy participants, and this would 
minimise the generalisability of evidence produced from 
weight management trials, particularly when assessing 
the impact of weight management programmes on men-
tal health. We must investigate how participant mental 
health influences attendance at follow-up assessments 
for behavioural weight management trials to determine 
whether participant samples accurately reflect the true 
range of mental health experiences.
The current study aimed to investigate whether base-
line mental health was associated with attendance and 
Trial registration: The original trial (ISRCT N8285 7232) and five year follow up (ISRCT N6498 6150) were prospectively 
registered with Current Controlled Trials on 15/10/2012 and 01/02/2018.
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engagement with a behavioural weight management 
programme and completion of follow-up assessments 
in a randomised controlled trial. By better understand-
ing the influence of baseline mental health on attendance 
and engagement, appropriate strategies may be imple-
mented to support participation, minimise attrition, and 
subsequentially benefit health. In this study, we embrace 
the continuum-based definition of mental health which 
appreciates that individuals can experience one or more 
symptoms of mental illness without meeting diagnostic 
criteria [30, 31]. 
Methods
Study design
This study is a secondary data analysis of the Weight 
loss Referrals for Adults in Primary care (WRAP) trial, 
a non-blinded, multi-arm, randomised controlled trial 
comparing three intervention arms: (1) Brief interven-
tion (BI), (2) 12-weeks commercial weight management 
programme (CP12), (3) 52-weeks commercial weight 
management programme (CP52). Participants who met 
eligibility criteria and gave informed consent were ran-
domly assigned to an intervention arm on a 2:5:5 ratio 
with a block size of 12, stratified by research centre 
and gender. More detailed trial methods are reported 
elsewhere [36]. Ethical approval up to two year post 
randomisation follow up was received by East of Eng-
land Cambridge East with local approvals from NRES 
Committee North West Liverpool Central and NRES 
Committee South Central Oxford. Ethical approval for 
five years post randomisation follow-up was received 
from West Midlands- Coventry and Warwickshire 
Research Ethics Committee 8th December 2017. The 
original trial (ISRCTN82857232) and 5 year follow up 
(ISRCTN64986150) were prospectively registered with 
Current Controlled Trials on 15/10/2012 and 01/02/2018 
(https:// doi. org/ 10. 1186/ ISRCT N8285 7232; https:// doi. 
org/ 10. 1186/ ISRCT N6498 6150).
Participants
Adults with a body mass index of 28 kg/m2 or greater 
were identified and recruited by local primary care prac-
tices across England. Exclusion criteria were: planned 
or current pregnancy in the next two years, previ-
ous or planned bariatric surgery, currently following a 
weight  loss programme, non-English Speaking or com-
munication needs that would preclude them from under-
standing the study materials and interventions, and 
general practitioner-defined inappropriate for participa-
tion (e.g., patients who are violent/terminally ill/have a 
history of an eating disorder). All participants gave writ-
ten informed consent.
Intervention
Participants randomly assigned to CP12 or CP52 were 
provided with vouchers to attend a weekly local WW 
(formerly Weight Watchers) meeting for the duration 
of the intervention they were assigned to (12-weeks or 
52-weeks). Participants were provided with a unique 
code to access the WW  digital tools for the duration 
of their assigned intervention. Participants assigned 
to the brief intervention control group were given a 
32-page printed booklet by the British Heart Founda-
tion of self-help weight-management strategies [37]. 
Research staff read a scripted booklet introduction to 
the participant.
Outcomes
Study participants completed outcome assessments at 
baseline, 3-, 12-, 24- and 60-months. The outcomes of 
interest in this study were:
• Attendance at WW sessions (i.e., programme attend-
ance): defined as the number of weekly WW sessions 
attended in the first 3 months of the programme 
(possible range of 0 to 12). Attendance at WW ses-
sions were categorised as low (≤  4 sessions), mod-
erate (> 4 and ≤ 8 sessions), or high (> 8 and ≤ 12 
sessions) attendance. Programme attendance was 
calculated by data collected by WW at weekly meet-
ings (participants were provided booklets of vouch-
ers to attend meetings, and WW reported how many 
vouchers were used). Data related to vouchers issued 
during a specific time period were not recorded due 
to a computer system error; as the only difference 
between those with and without data was referral 
date, missing data was considered to be missing at 
random.
• Engagement with WW digital tools (i.e., programme 
engagement): defined as (1) weekly frequency of 
use of the WW e-tools and online resources and 
(2) weekly frequency of use of the WW mobile 
phone app. The WW e-tools are an online service 
that includes access to support materials (e.g., reci-
pes, videos, community area) and tracking tools. 
Engagement with digital tools was self-reported at 
3-months from baseline, and answers were multiple 
choice (coded [1] Daily/almost daily, [2] 3–5 times 
per weeks, [3] 1–2 times per week, [4] Never/almost 
never).
• Study attendance (i.e., study visit attendance): defined 
as attendance at study clinic visits at 3-, 12-, 24- and 
60-month follow-up assessments. Study attendance 
was monitored by the research team and categorised 
as (1) did attend visit or (2) did not attend visit.
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Exposure variables were mental health-related meas-
ures at baseline, including quality of life (measured by 
EQ5D) [38], satisfaction with life (measured by the Satis-
faction with Life Questionnaire (SLQ)) [39], and depres-
sion and anxiety (measured by the Hospital Anxiety and 
Depression Scale (HADS)) [40].
The EQ5D, used to measure quality of life, has 5 dimen-
sions ([1] Mobility, [2] Self-care, [3] Usual activities, [4] 
Pain/discomfort, [5] Anxiety/depression) which are rated 
on 3 levels of severity (Level 1: No problem, Level 2: 
Some problems, Level 3: Extreme problems) [38]. Scores 
for the individual dimensions are collated to create a sin-
gle index score; we used the UK value set and algorithm 
to calculate the index scores used. Potential index scores 
range from −0.281 to 1, where an index score less than 
0 represents a state worse than death [41]. The EQ5D is 
a continuous measure derived from a validated question-
naire and is commonly used measure [38].
The Satisfaction with Life Questionnaire (SLQ) is a 
5-item, 7-point scale ([1] strongly disagree to [7] strongly 
agree) that measures an individuals’ perception of their 
satisfaction with their life as a whole, allowing the indi-
vidual to combine and weight aspects contributing to life 
satisfaction (e.g., health, finances, socialisation) according 
to their own criteria and judgement [39, 42, 43]. The SLQ 
score is calculated by adding the scores for each of the 
5-items, with a higher total score representing a greater 
sense of life satisfaction [39]. The SLQ is a valid and reli-
able scale, with suitability for a wide range of population 
groups [42, 43].
The HADS measure is a validated screening tool 
for anxiety and depression with 14 items (1:1 ratio for 
anxiety:depression) scored on a Likert scale from 0 to 3 
[40, 44, 45]. The scale produces symptom scores for anxi-
ety and depression that range from 0 to 21, with a score 
of equal to or greater than 11 representing moderate 
to severe symptoms of depression and/or anxiety [40, 
44, 45]. The scale cannot provide a clinical diagnosis of 
anxiety or depression [40, 44, 45]. The recent core out-
come set for trials of behavioural adult weight manage-
ment recommends the inclusion of the HADS measure to 
strengthen the consistency of reporting across trials [46].
Statistical analysis
Stata (version 16; College Station, TX) [47] was used for 
all statistical analyses. The aims of this secondary analysis 
were determined a-priori and comprehensive statistical 
analyses plan determined prior to obtaining the trial data. 
Descriptive summary statistics were calculated for base-
line characteristics by randomised group, with number of 
participants, mean, and standard deviation presented for 
continuous variables and number and proportion of par-
ticipants presented for categorical variables.
Association of mental health with programme attendance 
and engagement
Negative binomial regression was used to estimate the 
effect of participant mental health on programme attend-
ance, controlling for randomised group. Ordered logistic 
regression was used to estimate the effect on engagement 
with digital tools, controlling for randomised group. 
In the ordered logistic regression models, engagement 
response options were categorised as (1) Daily/Almost 
daily, (2) 3–5 times per week, (3) 1–2 times per week, and 
(4) Never/Almost never. Therefore, results were inter-
preted as the reduction in engagement associated with 
every unit change in mental health outcome. Analyses 
were performed using data from the intervention groups 
only (CP12 and CP52), and robust standard errors were 
calculated in all models to allow for clustering by general 
practice.
Association of mental health with study visit attendance
Logistic regression was used to estimate the associa-
tion between baseline participant mental health and 
attendance at study follow-up visits (at 3-, 12-, 24-, and 
60-months), controlling for randomised group and with 
robust standard errors to allow for clustering by general 
practice. Baseline mental health variables whose p-value 
for association with study visit attendance was < 0.05 
were included in mutually adjusted models. Analyses 




Between 18 October 2012 and 10 February 2014, 1269 
eligible participants were randomised to one of three 
groups. Two participants were excluded after the base-
line appointment and prior to the intervention started 
due to illnesses that rendered them ineligible for the trial. 
Figure  1 shows the participant flow through the trial. 
Participant characteristics at baseline are presented by 
randomised group in Table 1.
On average, participants attended approximately 10 
out of 12 WW sessions during the first 3-months of 
the study (12-week programme: 9.63 ± 3.44 sessions 
(80%); 52-week programme: 9.73 ± 3.41 sessions (81%)) 
(Table  2). Fifty-six percent of the 12-week programme 
participants and 50% of the 52-week programme par-
ticipants never or almost never used the WW e-tools 
or online resources (Table  2). A high proportion of the 
study participants never or almost never used the WW 
mobile phone app (12-week programme: 80%; 52-week 
programme: 73%) (Table 2).
The number of participants completing follow-up 
assessments was 1004 participants at 3-months (79%), 
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823 participants at 12-months (65%), 856 participants at 
24-months (68%), and 643 at 60-months (51%). Reasons 
for withdrawal from the study are detailed in Table 3.
Association of mental health with programme attendance 
and engagement
Association of mental health with attendance at WW sessions
Baseline scores for global quality of life (Incidence rate 
ratio (IRR) 1.06; 95% confidence interval (CI) 0.96, 1.17; 
n = 608), anxiety (IRR 1.00; 95% CI 0.99, 1.01; n = 625) 
and satisfaction with life (IRR 1.00; 95% CI 0.999, 1.01; 
n = 620) were not associated with attendance at WW ses-
sions in the first 3-months (Table  4). Every one unit of 
baseline depression score was associated with a 1% rela-
tive reduction in the rate of session attendance (IRR 0.99; 
95% CI 0.98, 0.999; n = 625) (Table 4).
Association of mental health with programme engagement
Baseline scores for global quality of life (Odds Ratio (OR) 
0.65; 95% CI 0.39, 1.09; n = 728), satisfaction with life (OR 
1.01; 95% CI 0.99, 1.03; n = 743), and depression (OR 1.00; 
95% CI 0.97, 1.04; n = 747) were not associated with weekly 
frequency of using WW e-tools/online resource (Table 5). 
Participants’ baseline score for anxiety was associated with 
self-reported engagement with the WW e-tools and online 
resources; every one unit of baseline anxiety was associ-
ated with 4% lower odds of reporting high levels of engage-
ment with the WW e-tools and online resources (OR 0.96; 
95% CI 0.94, 0.99; n = 747) (Table 5).
Association of mental health with engagement with WW 
mobile phone app
Anxiety (OR 0.98; 95% CI 0.95, 1.02; n = 749), depres-
sion (OR 1.00; 95% CI 0.96, 1.05; n = 749) and satisfaction 
with life (OR 1.02; 95% CI 0.996, 1.04; n = 745) at baseline 
were not associated with weekly frequency of using the 
WW mobile phone app (Table 5). Every one unit of base-
line global quality of life was associated with 69% lower 
odds of reporting high levels of weekly engagement with 
Fig. 1 Participant flow diagram (CONSORT)
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the WW mobile phone app (OR 0.31; 95% CI 0.15, 0.64; 
n = 730).
Association of mental health with study visit attendance
Association of mental health with attendance at 3‑month 
study visit
Every one unit of baseline global quality of life (OR 
1.95; 95% CI 1.20, 3.17; n = 1209) and baseline satisfac-
tion with life (OR 1.02; 95% CI 1.00, 1.04; n = 1209) were 
associated with a 95% and 2% higher odds of attending 
the 3-month study visit respectively. Conversely, every 
one unit of baseline anxiety (OR 0.95; 95% CI 0.92, 0.98; 
n = 1209) and baseline depression (OR 0.93; 95% CI 0.89, 
0.97; n = 1209) were associated with a 5% and 7% lower 
odds of attending the 3-month study visit (Table 6).
Baseline quality of life, satisfaction with life, anxiety, 
and depression were not associated with attendance at 
the 3-month study visit in the mutually adjusted model 
(Table 6).
Association of mental health with attendance at 12‑month 
study visit
Baseline global quality of life was not associated with 
attendance at the 12-months study visit (OR 1.48; 95% CI 
0.93, 2.37; n = 1227). A unit higher baseline satisfaction 
Table 1 Participant characteristics at baseline by randomised group
Abbreviations: WW Formerly Weight Watchers, BI Brief intervention, CP12–12 week commercial weight management programme (WW), CP52–52 week commercial 
weight management programme (WW), SD Standard deviation, BMI Body mass index, GCSE General Certificate of Secondary Education, A-Level – Advanced Level 
Qualification
Baseline characteristics
BI (n = 211) CP12 (n = 528) CP52 (n = 528)
Age (years) [mean ± SD] 51.91 ± 14.07 53.63 ± 13.26 53.30 ± 13.96
Female 143 (68%) 357 (68%) 359 (68%)
Body mass index (BMI: kg/m2) [mean ± SD] 34.43 ± 4.63 34.68 ± 5.39 34.45 ± 5.05
Self-reports taking antidepressant medication 26 (19%) 81 (21%) 81 (23%)
Anxiety [mean ± SD] 7.25 ± 4.29 6.89 ± 3.97 7.29 ± 4.09
Depression [mean ± SD] 5.58 ± 3.77 5.24 ± 3.38 5.20 ± 3.64
Ethnicity White or White British 181 (86%) 480 (91%) 475 (90%)
Asian or Asian British 9 (4%) 11 (2%) 15 (3%)
Black or Black British 5 (2%) 12 (2%) 6 (1%)
Mixed or multiple ethnic group 4 (2%) 4 (1%) 7 (1%)
Other, missing, or prefer not to say 12 (6%) 21 (4%) 25 (4%)
Index of Multiple Deprivation (IMD) decile 1 (least deprived) 16 (8%) 45 (9%) 44 (8%)
2 8 (4%) 16 (3%) 26 (5%)
3 12 (6%) 38 (7%) 32 (6%)
4 17 (8%) 37 (7%) 38 (8%)
5 31 (15%) 49 (9%) 50 (10%)
6 19 (9%) 61 (12%) 57 (11%)
7 32 (15%) 67 (13%) 63 (12%)
8 19 (9%) 69 (13%) 75 (14%)
9 12 (6%) 51 (10%) 47 (9%)
10 (most deprived) 45 (21%) 95 (18%) 94 (18%)
Level of education None 7 (3.57%) 25 (5%) 27 (6%)
GCSE or equivalent 55 (28%) 153 (32%) 155 (33%)
A-Level or equivalent 53 (27%) 95 (20%) 110 (24%)
Post-secondary study 10 (5%) 14 (3%) 10 (2%)
University degree or equivalent 48 (24%) 108 (23%) 97 (21%)
Higher degree or equivalent 23 (12%) 79 (17%) 68 (15%)
Household income £0–£19,999 65 (33%) 125 (25%) 138 (28%)
£20,000–£49,999 66 (33%) 173 (34%) 176 (35%)
£50,000+ 41 (21%) 91 (18%) 84 (17%)
Do not know / Prefer not to say 27 (14%) 113 (23%) 101 (20%)
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with life score was associated with 2% higher odds of 
attending the 12-month study visit (OR 1.02; 95% CI 1.00, 
1.04; n = 1227). A unit higher anxiety (OR 0.94; 95% CI 
0.91, 0.97; n = 1227) and baseline depression (OR 0.94; 95% 
CI 0.91, 0.98; n = 1227) score at baseline were associated 
with a 6% lower odds of attending the 12-month study visit 
(Table 6). Baseline satisfaction with life, anxiety, and depres-
sion were not associated with attendance at the 12-month 
study visit in the mutually adjusted model (Table 6).
Association of mental health with attendance at 24‑month 
study visit
Baseline global quality of life was not associated with 
attendance at the 24-months study visit (OR 1.61; 95% CI 
Table 2 Attendance and engagement with WW interventions, presented by intervention arm
Abbreviations: WW formerly Weight Watchers, SD Standard Deviation, CP12–12 week commercial weight management programme (WW), CP52–52 week commercial 
weight management programme (WW)
WW session attendance and engagement with programme resources
CP12 CP52
Attendance at WW sessions in first 3-months
(CP12 (n = 272); CP52 (n = 360))
Mean number of sessions attended (± SD) 9.63 ± 3.44 9.73 ± 3.41
Low attendance (n %) (≤4 sessions) 35 (13%) 55 (15%)
Moderate attendance (n %) (> 4 & ≤ 8 sessions) 33 (12%) 29 (8%)
High attendance (n %) (> 8 & ≤ 12 sessions) 204 (75%) 276 (77%)
Frequency of using WW e-tools/online resources
(CP12 (n = 355); CP52 (n = 400))
Daily/Almost daily 62 (17%) 91 (23%)
3–5 times per week 30 (8%) 40 (10%)
1–2 times per week 63 (18%) 67 (17%)
Never/Almost never 200 (56%) 202 (51%)
Frequency of using the WW mobile phone app
(CP12 (n = 356); CP52 (n = 401))
Daily/Almost daily 35 (10%) 60 (15%)
3–5 times per week 15 (4%) 15 (4%)
1–2 times per week 22 (6%) 32 (8%)
Never/Almost never 284 (80%) 294 (73%)
Table 3 Reasons for withdrawal from the study, presented by randomised group
Abbreviations: WW Formerly Weight Watchers, BI Brief intervention, CP12–12 week commercial weight management programme (WW), CP52–52 week commercial 
weight management programme (WW)
Withdrawal reasons
BI (n = 58) CP12 (n = 110) CP52 (n = 100)
Changed mind about participating 12 (21%) 21 (19%) 28 (28%)
Found another weight loss method 1 (2%) 2 (2%) 1 (1%)
Health issues 5 (9%) 16 (15%) 15 (15%)
Moved away 7 (12%) 17 (15%) 13 (13%)
No reason given 6 (10%) 16 (15%) 9 (9%)
Personal reasons 7 (12%) 12 (11%) 14 (14%)
Time/other commitments 6 (10%) 13 (12%) 9 (9%)
Trouble attending study visits 0 3 (3%) 1 (1%)
Unable to attend WW N/A 1 (1%) 2 (2%)
Unhappy with study procedures 0 2 (2%) 2 (2%)
Unhappy with intervention 14 (24%) 7 (6%) 6 (6%)
Table 4 Association of baseline mental health with attendance 
at WW sessions in first 3-months: Results are presented from 
negative binomial regression models, controlled for randomised 
group and with robust standard errors to allow for clustering by 
general practice
Abbreviations: WW Formerly Weight Watchers, CI Confidence interval
Attendance at WW sessions in first 3-months




Model 1: Global quality of life 1.06 (0.96, 1.17) 608
Model 2: Satisfaction with life 1.00 (0.999, 1.01) 620
Model 3: Anxiety 1.00 (0.99, 1.01) 625
Model 4: Depression 0.99 (0.98, 0.999) 625
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Table 5 Association of baseline mental health with weekly use of WW digital resources in first 3 months: Results are presented from 
negative binomial regression models, controlled for randomised group and with robust standard errors to allow for clustering by 
general practice
Abbreviations: WW formerly Weight Watchers, CI Confidence interval
Weekly frequency of using WW e-tools/online resources (reported at 3-months)
Mental health at baseline: Odds Ratio (95% CI) Number of participants
Model 1: Global quality of life 0.65 (0.39, 1.09) 728
Model 2: Satisfaction with life 1.01 (0.99, 1.03) 743
Model 3: Anxiety 0.96 (0.94, 0.99) 747
Model 4: Depression 1.00 (0.97, 1.04) 747
Weekly frequency of using the WW mobile phone app (reported at 3-months)
Mental health at baseline: Odds Ratio (95% CI) Number of participants
Model 1: Global quality of life 0.31 (0.15, 0.64) 730
Model 2: Satisfaction with life 1.02 (0.996, 1.04) 745
Model 3: Anxiety 0.98 (0.95, 1.02) 749
Model 4: Depression 1.00 (0.96, 1.05) 749
Table 6 Influence of baseline mental health on attendance at study follow-up visits: Results are presented from unadjusted and 
mutually adjusted logistic regression models. Mutually adjusted models are adjusted for baseline mental health variables that were 
statistically significant in unadjusted models. Baseline mental health variables that were not statistically significant in unadjusted 
models were not adjusted for in mutually adjusted models. All models were controlled for randomised group and clustering by 
general practice
Note: ^^ Not included in mutually adjusted model
Abbreviations: CI Confidence interval
Mental health at baseline: Attendance at 3-month study visit (Odds ratio (95% CI))
Unadjusted logistic regression (n = 1209) Mutually adjusted logistic regression (n = 1196)
Global quality of life 1.95 (1.20, 3.17) 1.25 (0.67, 2.30)
Satisfaction with life 1.02 (1.00, 1.04) 0.99 (0.97, 1.02)
Anxiety 0.95 (0.92, 0.98) 0.99 (0.94, 1.04)
Depression 0.93 (0.89, 0.97) 0.94 (0.87, 1.01)
Mental health at baseline: Attendance at 12-month study visit (Odds ratio (95% CI))
Unadjusted logistic regression (n = 1227) Mutually adjusted logistic regression (n = 1224)
Global quality of life 1.48 (0.93, 2.37) ^^
Satisfaction with life 1.02 (1.00, 1.04) 1.01 (0.98, 1.03)
Anxiety 0.94 (0.91, 0.97) 0.96 (0.92, 1.00)
Depression 0.94 (0.91, 0.98) 0.97 (0.93, 1.02)
Mental health at baseline: Attendance at 24-month study visit (Odds ratio (95% CI))
Unadjusted logistic regression (n = 1237) Mutually adjusted logistic regression (n = 1224)
Global quality of life 1.61 (0.97, 2.66) ^^
Satisfaction with life 1.03 (1.00, 1.05) 1.01 (0.99, 1.04)
Anxiety 0.94 (0.91, 0.97) 0.95 (0.91, 0.98)
Depression 0.95 (0.91, 1.00) 1.00 (0.95, 1.06)
Mental health at baseline: Attendance at 60-month study visit (Odds ratio (95% CI))
Unadjusted logistic regression (n = 1237) Mutually adjusted logistic regression (n = 1196)
Global quality of life 2.02 (1.27, 3.23) 1.41 (0.83, 2.38)
Satisfaction with life 1.03 (1.00, 1.05) 1.01 (0.98, 1.04)
Anxiety 0.95 (0.92, 0.98) 0.98 (0.95, 1.02)
Depression 0.94 (0.91, 0.97) 0.97 (0.92, 1.03)
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0.97, 2.66; n = 1237). A unit higher baseline satisfaction 
with life score was associated with a 3% increase in odds 
of attending the 24-month study visit (OR 1.03; 95% CI 
1.00, 1.05; n = 1237). A unit higher baseline anxiety (OR 
0.94; 95% CI 0.91, 0.97; n = 1237) and depression (OR 
0.95; 95% CI 0.91, 0.997; n = 1237) scores were associated 
with a 6% and 5% lower odds of attending the 24-month 
study visit (Table 6).
Baseline satisfaction with life and baseline depres-
sion did not remain associated with attendance at the 
24-month study visit when adjusted for baseline anxiety 
and depression (Table  6). When adjusted for baseline 
satisfaction with life and depression, a unit in baseline 
anxiety was associated with a 5% decrease in odds of 
attending the 24-month visit (OR 0.95; 95% CI 0.91, 
0.98); n = 1196).
Association of mental health with attendance at 60‑month 
study visit
A unit higher baseline global quality of life (OR 2.02; 95% 
CI 1.27, 3.23; n = 1237) and satisfaction with life (OR 1.03; 
95% CI 1.00, 1.05; n = 1237) scores were associated with a 
102% and 3% increase in odds of attending the 60-month 
study visit. Conversely, a unit higher baseline anxiety (OR 
0.95; 95% CI 0.92, 0.98; n = 1237) and depression (OR 
0.94; 95% CI 0.91, 0.97; n = 1237) scores were associ-
ated with a 5% and 6% decrease in odds of attending the 
60-month study visit (Table  6). Baseline quality of life, 
satisfaction with life, anxiety, and depression were not 
associated with attendance at the 60-month study visit in 
the mutually adjusted model (Table 6).
Discussion
In this study, we investigated whether participants’ men-
tal health was associated with the rate of attendance and 
engagement with the behavioural weight management 
programme (WW) and trial (WRAP). Lower levels of 
depression symptoms and higher scores for satisfaction 
with life at baseline were associated with higher rates 
of attendance at WW sessions  (i.e., higher rates of  pro-
gramme attendance). Similarly, adults with obesity who 
reported experiencing fewer symptoms of depression and 
anxiety and a higher satisfaction with life at baseline were 
more likely to report higher engagement with the pro-
gramme resources (WW e-tools and mobile phone app). 
We also found that those reporting greater quality of life 
at baseline were likely to have lower engagement with the 
WW mobile phone app than those with poorer quality of 
life, however this association was not consistent across 
study findings. Higher scores for quality of life and sat-
isfaction with life and fewer symptoms of depression and 
anxiety were also associated with higher attendance at all 
study visits up to 5 years follow-up.
Overall, we found that adults with obesity who self-
reported being more mentally healthy at baseline were 
more likely to attend programme sessions, engage with 
programme resources, and attend study follow-up assess-
ments. Previous research has reported that low levels of 
attendance and engagement in behavioural weight man-
agement trials are associated with decreased likelihood of 
achieving clinically significant weight loss, consequently 
reducing the likelihood of gaining the associated health 
benefits [9–11]. These findings highlight an emerging 
research priority to explore how to maximise the engage-
ment and retention of people experiencing poorer mental 
health.
It is important to note, however, that study findings 
should be interpreted with consideration to the loss of 
significance in mutually adjusted models and the magni-
tude of the effect sizes presented. Many significant asso-
ciations in univariable models became non-significant 
when mutually adjusted, potentially due to the mental 
health-related exposure variables being moderately cor-
related (Additional file 1: Table S1). Cross-correlation of 
exposure variables found correlations to range between 
small and large, with measures of anxiety and depres-
sion most highly correlated. Future research may con-
sider the use of a composite indicator by combining 
individual measures into a single index, therefore reduc-
ing the impact of multicollinearity. The effect sizes of 
the associations between mental health and attendance 
and engagement were considered to be small, suggest-
ing a small increase in risk of reporting lower attendance 
and engagement when reporting poor mental health at 
baseline [48]. However, these changes may still have a 
meaningful effect on the effectiveness of the behavioural 
weight management programme and trial. More research 
is needed to confirm the size of effect and investigate the 
potential impact on programme effectiveness and health 
outcomes.
Previous systematic review evidence has found no 
consistent psychological factors to be associated with 
attendance and engagement, but recommended further 
research into this area [7]. In the current study, we found 
poorer rates of attendance and engagement in those with 
poor mental health scores at baseline, aligning with the 
findings of McLean and colleagues who reported lower 
attendance among participants with higher levels of 
anxiety or depression [33]. Furthermore, current find-
ings also align with previous research reporting those 
with higher levels of anxiety or depression are more 
likely to report worse attendance and engagement with 
the weight management trial [13, 34]. Some previous 
research, however, has reported finding mental health to 
not be associated with attendance and engagement [14, 
35], contrasting with the findings of the current study. 
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This may be due to the differing classification of mental 
health within different studies. For example, Funderburk 
and colleagues defined mental health as diagnosed versus 
non-diagnosed with mental illness [35], whereas we con-
sidered mental health as a symptom-continuum which 
appreciates that participants can experience one or more 
symptoms of mental illness without meeting diagnostic 
criteria [30, 31]. This approach was selected as it is asso-
ciated with reduced stigma, and enables the investigation 
of a broader range of mental health outcomes [30–32].
There are many reasons why mental health might influ-
ence attendance and engagement with a behavioural 
weight management programme. Having poor men-
tal health can make participation and engagement dif-
ficult and, in particular, can make it difficult to engage 
in things that may interfere with self-soothing coping 
strategies (e.g., emotional eating) [49]. Many adults with 
obesity seek social support and socialisation from WW 
groups [50]. For those living with poor mental health, 
forming connections with others can be impeded by an 
increased likelihood to withdraw/isolate, be less vul-
nerable with others when forming connections, and be 
more likely  perceive others to judge them poorly (i.e., 
self-conscious/lacking self-esteem) [50]. In turn, those 
living with obesity and mental ill-health are likely to 
experience greater difficulties to connect with peers at 
the WW group than those who are mentally healthy, 
thus reducing the likelihood of programme attendance 
as their hopes and expectations of social support are not 
met. Previous negative experiences with healthcare pro-
viders (e.g., experiencing blame, shame, and discrimina-
tion for weight and/or mental health) may have reduced 
trust in services and healthcare staff, resulting in reduced 
engagement with services [49, 51]. Participants may also 
find that lack of immediate weight changes emphasises 
feelings of failure and shame, reduces their confidence 
in services’ effectiveness [52–55], and results in feelings 
of disappointment with the programme content [53]. 
Understandably, these feelings may decrease their moti-
vation to attend the programme sessions.
Future research could use qualitative approaches to 
explore the mechanisms underpinning why those with 
poor mental health are less likely to attend and engage 
with behavioural weight management programmes. The 
mechanisms influencing programme attendance and 
engagement may be individual-level, societal-level, or 
operate across multiple levels. Understanding of these 
mechanisms would enable development of approaches 
to combat this issue. Furthermore, future research might 
explore whether tailoring programmes for those with 
obesity and poor mental health may result in improved 
programme attendance and engagement. For exam-
ple, the RAINBOW trial provided a tailored weight 
management programme for persons with obesity 
and depression, finding modest improvements in both 
weight and depression symptoms [56]. We are unaware, 
however, if the tailored programme resulted in greater 
attendance and engagement rates than similar individu-
als attending a standard behavioural weight management 
programme.
The findings of the current study suggest that follow-
up participant samples are less likely to include people 
with poorer mental health at baseline. Potential explana-
tions may be higher levels of anxiety regarding clinical 
assessments (e.g., blood-sampling), lack of confidence in 
trial effectiveness (e.g., lack of immediate results), dis-
comfort answering personal questionnaires (e.g., psycho-
logical assessments), and perceived participant burden 
(e.g., unhappy with length of questionnaires about men-
tal health) [57–59]. Previous evidence from behavioural 
weight management trials should not be discarded, how-
ever caution should be taken when interpreting findings. 
In future trials, researchers should consider implement-
ing a participant retention strategy that supports those 
with poorer mental health at baseline.
Strengths and limitations
It is uncommon for behavioural weight management tri-
als to measure and report mental health outcomes [6]. 
This secondary analysis of the WRAP trial benefited from 
the inclusion of multiple mental health outcomes at each 
assessment. Study findings were limited to those mental 
health measures implemented in the WRAP trial, the 
primary focus of which was the impact on weight and 
related outcomes [36]. Mental health measures not col-
lected in this trial may further explain participant attend-
ance and engagement rates, such as social support, stress, 
loneliness, self-esteem, and self-efficacy. Future research 
should aim to measure a wide range of mental health 
outcomes, but this must be balanced against participant 
burden.
A limitation was the large proportion of missing data, 
specifically for attendance at WW sessions and engage-
ment with the WW resources. We had pre-specified 
a sensitivity analysis using multiple imputation, but 
also pre-specified that this would not be appropriate 
if the level of missingness were 25% or more (as it was 
for the programme attendance and engagement analy-
ses), and would not be necessary if the level of missing-
ness were less than 5% (as it was for the analysis of study 
attendance).
In addition, it is worth noting that engagement with 
WW digital resources and the mobile phone app was 
assessed using a self-report questionnaire and is there-
fore subject to potential error and bias, such as recall 
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error and social desirability bias. To increase the accu-
racy of engagement data going forward, we recommend 
the use of objective measures either in replacement or in 
combination with self-report measures.
Despite these limitations, this study contributes 
new evidence to the field  by seeking to understand 
the factors impacting attendance and engagement in 
behavioural weight management trials. To our knowl-
edge, this study is one of the first to explicitly focus 
on the impact of mental health on programme and 
study attendance and engagement. We investigated 
the impact of participant mental health on numerous 
attendance and engagement factors and found rela-
tively consistent evidence across factors. The aims of 
this secondary analysis were determined a priori, with 
a comprehensive statistical analyses plan determined 
prior to obtaining the trial data. The WRAP trial ben-
efits from the randomised controlled trial design and 
minimal eligibility criteria that increase the representa-
tive nature of the baseline participant sample relative to 
the general population of adults with obesity in the UK.
Conclusions
This study shows that adults with obesity attending a 
behavioural weight management programme are less 
likely to attend programme sessions, engage with pro-
gramme resources, and attend study follow-up visits 
if they report higher levels of depression and anxiety, 
and lower scores for quality of life and satisfaction with 
life at baseline. The small effect sizes reported suggest 
a small increase in odds of low attendance and engage-
ment in those experiencing poor mental health at base-
line, however the changes may still have a meaningful 
effect on programme effectiveness and trial comple-
tion. Lower attendance and engagement are associated 
with reduced likelihood of achieving clinically sig-
nificant weight loss and the associated health benefits, 
highlighting the importance of maximising participant 
attendance and engagement in behavioural weight 
management programmes. Future research should 
explore the effectiveness of targeted strategies to max-
imise attendance and engagement in those report-
ing poorer mental health upon entering a behavioural 
weight management programme or trial. Additionally, 
researchers should ensure to apply appropriate caution 
when interpreting trial findings, and sufficiently control 
for potential bias due to mental health when conduct-
ing trial analyses.
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